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Abstract
The accumulation of the ß-amyloid peptide (Aß) is a cen-
tral event in the pathogenesis of Alzheimer’s disease
(AD). Aß removal from the brain by immune therapy
shows promising potential for the treatment of patients
with AD, although the mechanisms of the antibody
action are incompletely understood. In this study we
compared the biological activities of antibodies raised
against various Aß fragments for Aß reduction in vitro
and in vivo. Antibodies against Aß enhanced the uptake
of Aß42 aggregates up to 6-fold by primary microglial
cells in vitro. The kinetics of Aß42 uptake varied consider-
ably among antibodies. Based on the activity to mediate
Aß42 uptake by microglial cells, we identified a bioactive
antibody that significantly reduced Aß42 levels in the
brains of transgenic mice with neuronal expression of an
AD-related mutated amyloid precursor protein. This ef-
fect depended on the epitopes recognized by the anti-
body. Our data suggest that the ability to facilitate Aß42
uptake by primary microglia cells in vitro can be used to
predict the biological activity of the antibody by passive
immunization in vivo. This protocol may prove useful for
the rapid validation of the activity of antibodies designed
to be used in immune therapy of AD.
Copyright © 2004 S. Karger AG, Basel
Introduction
Alzheimer’s disease (AD), the most common cause of
dementia, is an age-related neurodegenerative disorder
that is characterized by progressive cognitive deficits,
such as memory loss and a decline in mental abilities. An
elevated abnormal level of the ß-amyloid peptide (Aß) in
the brain is the key step in the pathogenesis of AD [1–3].
Aß is associated with the formation of neurofibrillary tan-
gles [4, 5] with impaired synaptic functions and the loss of
neurons. Therefore, a major emphasis of AD therapy has
currently been on the removal of Aß from the affected
brains.
Both active and passive immunization approaches
were effective in reducing the brain Aß levels in human
patients and in AD mouse models expressing AD-causing
mutations of amyloid precursor protein (APP) resulting in
a massive production of Aß and age-dependent amyloid
plaque deposition [6–10]. In addition, anti-Aß immuniza-
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Fig. 1. Schematic presentation of different Aß fragments that were used to generate the monoclonal antibodies.
Letters represent amino acids according to the single letter code. Numbers represent amino acid position within the
peptide starting at the N-terminus of the Aß peptide. Bars correspond to the peptide that was used for immunization
to generate the respective antibody. Balls define the ends of peptides used for immunization. Arrowheads indicate
that the used peptides reached to the N-terminus of Aß.
tions exerted beneficial effects on cognitive performances
of transgenic mouse models of AD [11, 12] and in human
subjects [13], providing the functional evidence for the
validity of the Aß immune therapy. Furthermore, we have
recently shown that anti-Aß immune therapy protected
the neurons against apoptotic stimuli in an AD mouse
model [10].
Mechanisms implicated in the reduction of brain Aß
by antibodies may include acting as a peripheral sink to
reduce cerebral Aß levels without entering the brain [7].
Alternatively, antibodies may penetrate into the brain,
bind the Aß and interfere with its aggregation [8, 14, 15].
Finally, upon opsonization of Aß by antibodies, the Aß/
antibody complex is phagocytosed by brain microglial
cells in both an Fc receptor-dependent and independent
manner [8, 14, 16].
Even though potent in reducing brain Aß, immune
therapy was shown to provoke aberrant autoimmune
response such as meningoencephalitis or cerebral hemor-
rhages in human subjects or mice [17–19], indicating that
under certain circumstances, immunization could lead to
adverse side effects. Despite intense research and clinical
interest in Aß immunization, the mechanisms by which
antibodies result in clearing Aß from the brain are contro-
versial. It is unclear why some antibodies enter the brain
and clear Aß, whereas some similar antibodies are ineffec-
tive in the same system [8] and what the mechanisms of
action of the proposed peripheral sink are. Moreover, the
immunization protocol and the epitope of Aß chosen for
immunization may affect the outcome of the active im-
munization [20–22]. Therefore, it is desirable to design a
rapid method for predicting the bioactivity of anti-Aß
antibodies by an in vitro test system. In this study the effi-
cacy of microglia cells to take up and degrade Aß in vitro
was used for an initial screening of anti-Aß antibodies
active in vivo. We then verified the bioactivity of anti-Aß
antibodies with a passive immunization protocol in vivo.
We assessed the efficacy of these antibodies to reduce
brain Aß42 levels and showed that the bioactivity of anti-
bodies against Aß is dependent on the epitope recognized
by these antibodies.
Material and Methods
Hybridoma Cultures and Antibody Production
The monoclonal antibodies were raised against full-length Aß
peptide or its fragments (fig. 1) and the produced antibodies were
tested to recognize the respective peptides and the full-length Aß pep-
tide by Western blotting. Hybridoma clones producing antibodies
against various fragments of the Aß peptide were cultured in OPTI-
MEM 1 (Gibco) containing 10% heat-inactivated fetal bovine serum
(FBS) and penicillin/streptomycin. The FBS concentration was grad-
ually reduced to a final concentration of 0.1%. Conditioned media
were collected and the antibodies were purified via protein A col-
umns (Mo Bi Tech). In brief, the protein A column was washed with
15 ml of 1! binding buffer (1 M glycine, 0.15 M NaCl, pH = 8.6) at a
flow rate of 1 ml/min. Conditioned media were mixed 1:1 with 2!
binding buffer and pumped through the column at 1 ml/min at room
temperature. Columns were then washed with 30 ml of 1! binding
buffer and antibodies were eluted with elution buffer (0.1 M citrate,
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pH 5.5 and pH 3), desalted and neutralized by dialysis against PBS
overnight. The subclass of purified anti-Aß antibodies was deter-
mined using the monoclonal antibody isotyping kit (Boehringer
Mannheim) according to the supplier’s protocol.
Primary Microglia Cultures
Primary cultures of mixed glia were prepared from newborn
C57BL/6J mice. Meninges, olfactory bulb and hippocampus were
removed from brain hemispheres. Neocortical tissue was dissociated
by incubation with dissociation solution (0.02% EDTA, 0.24%
HEPES, 6.6% trypsin and 0.8% DNase I in DMEM) for 15 min at
37°C followed by an incubation in DMEM (Gibco) containing 10%
FBS and 1.6% DNase I for 15 min at 37°C and subsequent triturat-
ing by a set of fire-polished glass pipettes of descending diameter.
Tissue homogenates were passed through a nylon mesh of 24 Ìm
pore size (Millipore). 5 ! 106 cells were plated per T25 flasks and
grown in DMEM medium containing 10% FBS to confluency within
10 days. Culture medium was changed after 24 h and every 3 days
thereafter. After 14 days microglial cells started to proliferate and
floated at the surface of the medium. Loosely attached cells could be
mobilized by gentle shaking of the culture. Microglial cells were har-
vested by aspiration of the supernatant fluid, centrifuged at 100 g for
5 min and resuspended in culture medium. For immunocytochemis-
try, cells were plated on glass coverslips coated with poly-D-lysine
(30–70 kD, Sigma) at a density of 10,000 cells/cm2 (low-density cul-
tures). For quantification of Aß uptake, cells were cultured in 96-well
plates at a density of 100,000 cells/well (high-density cultures). Ten
minutes after plating, the microglial cells were adherent and nonad-
herent cells were eliminated by gently rinsing the cultures with
medium. Lectin immunostaining identified more than 95% of cells
in these cultures as microglial cells.
In vitro Studies
Synthetic human Aß42 (1 mg/ml, Bachem) was fibrillized in PBS
as described [23]. For qualitative evaluation of Aß42 uptake in micro-
glial cells by immunohistochemistry, the Aß42 stock was diluted 1:10
with anti-Aß antibody solutions (300 Ìg/ml) and incubated overnight
at 4°C in a rotary shaker at 5 rpm to generate an Aß42/antibody com-
plex. For quantitative determination of microglial uptake by ELISA,
Aß42 stock solution was mixed in a 1:1 ratio with the antibody solu-
tions to generate the Aß42/antibody complex.
Aß42/antibody complexes were diluted 20 or 33 times in culture
medium before incubation with low- or high-density cultures, respec-
tively. Three days later the low-density cultures were washed with
PBS, fixed with ice-cold methanol for 10 min and subjected to immu-
nocytochemistry. High-density cultures were incubated with Aß42
complexes for 2, 24 or 72 h. After several washes, the cultures were
then subjected to formic acid extraction and ELISA measurement of
cellular Aß. Control cultures were incubated with fibrillar Aß42 alone.
To control for unspecific binding of complexes to the culture dish,
complexes were also incubated in cell-free wells.
Aß Extraction from Microglia Cultures
High-density cultures were incubated with Aß42/antibody com-
plex or fibrillar Aß42 alone for 2, 24 and 72 h. Cells were washed 3
times with PBS, lysed with 70% formic acid and the resulting extracts
were neutralized by addition of 20-fold volume of 1 M Trizma base.
Internalized microglial Aß content was quantified by ELISA as
described [10, 23]. At least three wells were treated with each anti-
body in each experiment.
Immunostaining and Western Blotting
After fixation, cultures were washed 3 times with PBS for 5 min
and blocked in 10% goat serum for 30 min before incubation with
Griffonia simplicifolia isolectin B4 (2 Ìg/ml, Vector) in PBS contain-
ing 0.1% Triton X-100 for 48 h at 4°C. After 3 washes with PBS, cells
were incubated with anti-lectin (Vector) and anti-Aß antibodies
(4G8, Signet) in PBS containing 1% goat serum and 0.1% Triton
X-100 for 2 h at room temperature. For double staining against Aß
and lysosomes, the 4G8 antibody was combined with the anti-lyso-
somal-associated membrane protein-1 (LAMP-1) antibody (South-
ernBiotech). In addition, Iba1 [24, 25] antibody was also used to
assess microglia activation.
For analysis of APP processing and microglia activation by West-
ern blotting, mice were anesthetized and perfused transcardially with
ice-cold PBS. Frontal parts of the brains reaching from the stereo-
taxic coordinates interaural 6–5 were homogenized and subjected to
Western blotting as described [10, 23]. The remaining parts of the
brains were fixed in 4% paraformaldehyde, washed several times in
PBS and 35-Ìm frontal sections were prepared. After electrophoresis,
blots were probed with 6E10 (Signet) and C-terminal APP (Sigma)
antibodies to study possible alterations of APP processing due to
antibody treatments, as well as Iba1 antibody for quantification of
the activation status of microglia. Blots were stripped and probed for
ß-actin (Abcam) as a loading control [10]. Similarly, to test whether
the monoclonal anti-Aß antibodies recognize transgenically ex-
pressed Aß, similar amounts of a brain homogenate of an age-
matched SwAPP mouse were loaded onto the gel and probed with the
monoclonal anti-Aß antibodies (50 Ìg/ml).
Passive Immunization
Transgenic mice with neuronal expression of the Swedish double
mutation of APP (SwAPP mice) were bred and housed as described
[10, 23]. SwAPP mice were passively immunized by intravenous
(i.v.) injections of several monoclonal anti-Aß antibodies. Each
mouse was given four injections into the tail vein of 9 mg antibody/kg
body weight at intervals of 5 days beginning at 6–7 weeks of age (n =
3–4 per group) [10]. Mice were sacrificed the day after the last anti-
body injection. Titers of anti-Aß antibodies and levels of Aß42 were
measured in sera and compared to the corresponding values prior to
the injections as previously described [10, 23], and correlated to Aß42
levels in the brains of the same mice. The control group comprised
untreated age-matched SwAPP littermates (n = 4).
Statistical Analysis
Data were collected by investigators blinded to the experimental
setup and were analyzed by the nonparametric Mann-Whitney U
test. In all graphs, means B SEM are shown.
Results
Microglial Cells Internalized Fibrillar Aß42 and
Aß42/Antibody Microaggregates in vitro
To discriminate between antibody-dependent and an-
tibody-independent uptake of Aß42 by microglial cells in
vitro, primary microglial cells were incubated for up to 3
days with either fibrillar Aß42 alone or with Aß42/antibody
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j
Fig. 2. Accumulation and phagolysosomal localization of Aß42 by
microglial cells. Aß42 alone (a–c) or Aß42/antibody complex (d–i)
were incubated with low-density cultures of primary microglial cells
for 24 h and stained with antibodies against Aß (4G8, a, d, g) and
lectin (b, e) to identify Aß and the microglial cells, respectively.
Microglial cells took up Aß42 both if it was applied as a complex with
specific antibodies (d–f, g–i) or if applied alone (a–c). 4G8-immu-
noreactive material was accumulated in granular structures around
the nucleus of microglial cells (a, d and c, f overlay). In addition,
cultures were doubly immunostained against Aß and a lysosomal
marker (LAMP-1). LAMP-1-reactive structures (h) and Aß-positive
structures (g) showed a broad overlap (i), indicating phagolysosomal
localization of Aß in microglial cells. j Quantification and kinetics of
Aß42 uptake by microglial cells. Microglial Aß42 levels extracted by
formic acid depended on the antibody used and on the incubation
time. Measurements were made at time points 2, 24 and 72 h and
represented as absolute cellular Aß42 content. Scale 100 Ìm.
complex of Aß42 with various monoclonal anti-Aß anti-
bodies generated against the entire Aß peptide or its N
versus C terminal fragments (fig. 1). Immunoreactivity
with G. simplicifolia isolectin B4 identified the cultured
microglia. Cultures were examined by double immuno-
staining with microglial and Aß markers. Aß immunoreac-
tivity was associated with microglial cells, indicating that
microglial cells take up fibrillar Aß42 and the Aß42/anti-
body complexes. Microglial cells accumulated Aß42 both
when fibrils were applied alone (fig. 2a–c) and as a com-
plex (fig. 2d–i). To further exclude that Aß42 is only
absorbed to the surface of microglial cells but not internal-
ized, cultures were double-stained for Aß and a lysosomal
antigen (LAMP-1). Aß and LAMP-1 immunofluorescence
showed a broad overlap (fig. 2g–i), indicating that double-
stained structures correspond to phagolysosomes contain-
ing Aß.
To compare the efficacy of the purified antibodies to
mediate uptake of fibrillar Aß42 by microglia, microglia-
associated Aß42 was quantified by ELISA in cell extracts
(fig. 2j). These measurements revealed a basal antibody-
independent uptake of Aß42 by microglial cells. Up to 6-
fold higher Aß42 levels were found in microglia cells that
were incubated with the Aß42/antibody complex when
compared to incubation of the cells with Aß alone (fig. 2j).
Both efficacy and kinetics of Aß42 uptake by microglia
cells differed between antibodies used for the formation
of Aß42/antibody complexes. Maximum Aß42 uptake was
reached after 3 days for most of the complexes, except for
22C4 where the amount of cellular Aß42 was highest at
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Fig. 3. Passive immunization of SwAPP mice. a Elevated levels of
anti-Aß antibody titers were measured at the time of perfusion in sera
of all SwAPP mice injected peripherally with identical amounts of
purified antibodies. The values are expressed as fold increase, rela-
tive to corresponding serum antibody levels of 23 aged-matched
untreated SwAPP mice that was set as 100%. b Aß42 concentrations
in brain homogenates and sera of SwAPP mice injected peripherally
with purified anti-Aß antibodies. The values are expressed in percent
relative to a 100% baseline of the corresponding values obtained
from averaging readings from a control group of 4 noninjected
SwAPP littermates (* p ^ 0.05, *** p ^ 0.001). Note that no group
revealed a significant change of the Aß42 concentrations in serum
relative to the baseline. c All anti-Aß antibodies used in the immuni-
zation study recognized the human transgenic Aß expressed in
SwAPP brains. The same SwAPP brain homogenate was loaded onto
all lanes and the antibody 6E10 served as positive control.
24 h. For 22C4 clone, intracellular Aß42 levels reached
basal levels after 3 days, indicative of a rapid uptake of
Aß42 and its degradation between 1 and 3 days (fig. 2j).
While 8G7 mediated a constant increase of microglial
Aß42 over time, 22D4 was completely ineffective in facili-
tating Aß42 uptake. Thus, this experimental system allows
for quantifying the efficacy of antibodies to mediate Aß42
uptake in vitro.
To determine whether the varying effects mediated by
different antibodies to take up and degrade Aß42 by
microglia cells may be related to different subtypes of
IgG, we isotyped the anti-Aß antibodies used in this
study. All antibodies were identified as IgG1-containing Î
light chains, thus eliminating the possibility that different
antibody subtypes may be responsible for the observed
effects.
In vivo Activity of Anti-Aß Antibodies
The effectiveness of anti-Aß antibodies to reduce the
Aß levels in vivo was studied by i.v. injection of purified
antibodies into the tail vein of SwAPP mice. Hybridoma
clones were selected on the basis of their varying kinetics
to mediate Aß uptake by primary microglia in vitro and
attention was paid to choose clones generated against
defined fragments of Aß. In addition, one chosen clone
recognized only Aß40 but not the Aß42 molecule.
Serum anti-Aß antibody levels were assessed by analy-
sis of the blood samples taken at the time of perfusion and
were compared to baseline antibody levels of 23 untreated
age-matched SwAPP littermates (fig. 3a). Antibody titers
of the individuals receiving i.v. antibody injections in one
group revealed little variation. This finding was expected
because a standard amount of purified antibody (adjusted
to the body weight of each mouse) was peripherally
administrated. Strikingly, even though the same amount
of antibody was injected for all groups, the level of anti-
body detectable in serum was lower for 8G7-injected mice
(fig. 3a), probably due to a faster turnover of this antibody
in vivo.
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Finally, Aß42 concentrations in sera and brains of
SwAPP mice, peripherally injected with purified anti-
bodies, were assessed (fig. 3b). The injection of the anti-
body 22C4 caused a 55% reduction of brain Aß42 levels
(p ^ 0.05), while mice injected with 8G7 and 9G10 anti-
bodies showed an unexpected significant elevation of
cerebral Aß42 levels. The elevation of Aß42 levels after
10G8 injections did not reach statistical significance
(fig. 3b). The levels of Aß42 correlated significantly in the
serum and brains of treated mice (Pearson-Spearman cor-
relation coefficient = 0.646, p ^ 0.05). For mice injected
with the 22C4 antibody, a strong negative correlation was
found between the anti-Aß antibody levels in serum and
the Aß42 concentrations in the brain (correlation coeffi-
cient: –0.98, p ^ 0.01). In addition, i.v. antibody injec-
tions did not change serum Aß42 levels in any group
(fig. 3b). Moreover, Western blot analysis on SwAPP
brain homogenates revealed that all antibodies recog-
nized the Aß expressed in these brains (fig. 3c).
When compared to untreated brains, no consistent
change in APP processing or microglia activation could be
detected by Western blotting in brains of mice as a result
of passive immunization (not shown).
Discussion
The aim of this study was to set up a system to compare
the ability of different monoclonal anti-Aß antibodies,
raised against different fragments of the Aß peptide, to
mediate the uptake and degradation of Aß42 in vitro and
in vivo. The results of this study show that antibody-
mediated Aß42 uptake by primary microglia cells in vitro
can be used as a measure to predict the bioactivity of anti-
Aß antibodies in vivo.
To compare the efficacy at which Aß42 was taken up by
the microglial cells when applied as a complex with var-
ious antibodies, internalized Aß42 in microglial cells was
quantified by ELISA. Different antibodies varied in their
activity to mediate uptake of Aß, both for the overall
amount of Aß42 taken up and also for the kinetics of this
uptake, indicating that the degradation of Aß42 is affected
by the complexing antibody. These variations cannot be
explained by differences in antibody subclasses, which are
known to differ in their opsonization capacities because
all antibodies included in this test belonged to the same
subclass.
Active and passive immunization against fibrillar Aß
have proven to be powerful tools in reducing or prevent-
ing amyloid pathology in transgenic mice overexpressing
human mutant APP [7–9, 11, 12, 15, 21] and in human
subjects [6]. It is, however, not yet understood why some
anti-Aß antibodies are potent in removing Aß from the
brain, whereas others are ineffective, even though they
recognize Aß in vitro [8].
Other than by mediating microglial uptake of Aß, anti-
bodies against the peptide may also clear Aß from the
CNS and plasma by inducing a shift in the equilibrium
between the two compartments and facilitate Aß flux
from a central to a peripheral compartment [7, 26]. More-
over, an efficient receptor-mediated bidirectional trans-
port mechanisms for Aß was shown at the blood-brain
barrier that transports the peptide from the CNS to plas-
ma, as well as from plasma to the CNS [26].
Our data are in agreement with studies showing a scav-
enger receptor-mediated basal Aß uptake by microglial
cells without the action of antibodies and that this uptake
is increased by anti-Aß antibodies [27, 28]. In a similar
study, however, an anti-Aß antibody increased Aß uptake
solely 1.5-fold [27], whereas we observed an up to 6-fold
increase of Aß uptake by microglial cells after antibody
treatment. The reasons for the varying capacity of the
antibodies to facilitate Aß uptake may be found in the
epitope recognized by the antibody (17–24 on Aß peptide)
and in the antibody subtypes (IgG2) used in that study
[27]. Furthermore, passive immunization with an anti-
body against Aß of the IgG1 subtype was recently shown
to increase the FcÁ receptor expression on microglia in
SwAPP mice and led to a reduction of amyloid pathology
[29], suggesting an active role of antibodies to promote
the clearance of Aß by microglial cells in vivo.
We chose young SwAPP mice without plaque patholo-
gy to assess antibody-mediated changes in soluble Aß,
because concentrations of the soluble Aß correlate consid-
erably with the degree of cognitive impairment in AD
patients [30, 31]. Moreover, we were most interested in
Aß42 because it represents the predominant amyloidogen-
ic Aß species and its levels are massively increased in the
progression of pathology in both AD patients and APP
transgenic mouse models.
At the time of perfusion, high levels of anti-Aß anti-
body titers were measured in all mice injected peripher-
ally with purified antibodies. The antibody level in sera of
mice injected with 8G7 was markedly lower, even though
exactly the same amounts of antibody had been injected.
We postulate that these differences are probably attribut-
able to a variability in the biological activity or antibody
turnover in vivo. When compared to untreated SwAPP
littermates (baseline), brain Aß42 concentrations were sig-
nificantly lower in mice treated with 22C4 and unex-
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pectedly increased in mice injected with antibodies 8G7
and 9G10. We could not assess whether the antibodies
were able to effectively bind soluble Aß in the brain. All
antibodies used here, however, could recognize Aß in
SwAPP brain homogenates on Western blot level and all
have facilitated Fc receptor-mediated microglial uptake
of fibrillar Aß42 in vitro, suggesting that they could inter-
act with the Aß peptide.
The absence of an effect on the brain levels of soluble
Aß42 can be explained by the failure of the antibodies to
bind Aß effectively in the periphery and thus exert the
effect of a peripheral sink or by the inability to enter the
brain and induce enhanced microglial uptake of Aß. The
observed increase of Aß42 concentrations in the brains of
mice injected with antibodies 8G7 and 9G10, however,
are in stark contrast to most published studies on the
peripheral passive immunization with anti-Aß anti-
bodies, suggesting that anti-Aß antibodies differ in their
ability to reduce Aß42 levels when used in the same experi-
mental setup. Similar increases in brain Aß levels after
anti-Aß immunization, however, have been shown in oth-
er studies [32, 33], indicating again that a shift between
Aß levels of the CNS and periphery is bidirectional and
the net effect depends on the antibody used and on the
mode of antibody application.
In the present study we show that the bioactivity of
anti-Aß antibodies depended on the epitope recognized.
More importantly, the ability of an anti-Aß antibody to
mediate Aß42 uptake by primary microglial cells can pre-
dict its bioactivity to reduce the brain levels of Aß42 in
vivo. The collected data establish a framework for the
evaluation and identification of in vivo active antibodies.
In this respect, our data will help to design further experi-
ments aiming at the refinement of amyloid-lowering strat-
egies in vivo.
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